Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Document Type
Article
Abstract
A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease. © 2007 Nature Publishing Group.
Publication Date
11-1-2007
Publication Title
Nature Medicine
ISSN
10788956
E-ISSN
1546170X
Volume
13
Issue
11
First Page
1359
Last Page
1362
PubMed ID
17934472
Digital Object Identifier (DOI)
10.1038/nm1653
Recommended Citation
Ray, Sandip; Britschgi, Markus; Herbert, Charles; Takeda-Uchimura, Yoshiko; Boxer, Adam; Blennow, Kaj; Friedman, Leah F.; Galasko, Douglas R.; Jutel, Marek; Karydas, Anna; Kaye, Jeffrey A.; Leszek, Jerzy; Miller, Bruce L.; Minthon, Lennart; Quinn, Joseph F.; Rabinovici, Gil D.; Robinson, William H.; Sabbagh, Marwan N.; So, Yuen T.; Sparks, D. Larry; Tabaton, Massimo; Tinklenberg, Jared; Yesavage, Jerome A.; Tibshirani, Robert; and Wyss-Coray, Tony, "Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins" (2007). Neurology. 806.
https://scholar.barrowneuro.org/neurology/806